125 / 1266
Median overall survival ranged between 16.0 and 38.4 months for ND-GBM and
between 9.6 and 35.9 months for Rec-GBM.
Vaccine-related side effects were in general mild (grade I and II), with
serious adverse events (grade III, IV and V) reported only rarely.
DC immunotherapy appears to have the potential to increase the overall
survival in patients with HGG, with an acceptable side effect profile. The
findings will require confirmation by the ongoing and future phase III
trials.
59
DC-Vax